MedTrace Logo

Safety and Efficacy of CMD03 CAR T Cell in Children With Relapse or Refractory Solid Tumors

NCT06612645 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2026-03-02

No results posted yet for this study

Summary

A Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.

Conditions

  • Pediatric Cancers
  • Solid Tumor Pediatric

Interventions

BIOLOGICAL

B7H3-IL7Ra CAR-T cells

Autologous T cells lentiviral transduced to express a B7H3-specific chimeric antigen receptor (CAR) with the addition of an IL-7 receptor alpha signaling domain, administered via central venous access catheter after lymphodepletion

Sponsors & Collaborators

  • King Chulalongkorn Memorial Hospital

    collaborator OTHER

  • Chulalongkorn University

    lead OTHER

Principal Investigators

  • Piti Techavichit, Associate Professor, MD · Chulalongkorn University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
25 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-01
Primary Completion
2027-12-01
Completion
2028-12-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06612645 on ClinicalTrials.gov